Download

Download Full Text (829 KB)

Description

Lichen planus (LP) is an autoimmune disorder mediated by T-cells, where inflammatory cells target an unidentified protein in the skin and mucosal keratinocytes.

LP affects 1 in 100 individuals globally, primarily adults over the age of forty. • About 50% of LP patients develop oral lesions, occurring more often in women compared to men.

Cutaneous LP often clears within a few years while mucosal LP can persist for more than a decade.

Genetic predisposition, stress, tissue injury, contact allergy, and drug reactions are risk factors.

Common treatment options: Topical and intralesional corticosteroids, topical immunosuppressants (tacrolimus and pimecrolimus).

There is some evidence supporting the efficacy of upadacitinib in achieving rapid resolution of oral LP.

Publication Date

5-9-2024

Disciplines

Dermatology

Comments

2024 Alvin Yarrows Research Day at Corewell Health Hospital Farmington Hills, Farmington Hills, MI, May 9, 2024.

Efficacy of Upadacitinib in Resolving Refractory Oral Lichen Planus: A Case Study

Included in

Dermatology Commons

Share

COinS